Grünenthal to capitalize on Axxam's drug discovery platform

Family-owned German drugmaker Grünenthal has entered into a collaboration with Italian biotech company Axxam.

The objective is to discover novel small molecule lead structures for the development of pain and inflammation therapeutics by combining Axxam’s drug discovery platform with Grünenthal’s expertise on emerging and innovative biological pathways and targets. No financial terms of the accord were disclosed.

The collaboration aims to support Grünenthal’s objective to identify compounds that could help patients with pain or inflammatory diseases, a focus of the research-based pharmaceutical company. Axxam will apply its integrated and innovative early drug discovery platform by combining it with its extensive expertise for innovative biological pathways and targets. This will include assay development, screening activities, Hit finding and follow up activities.